News | Pharmaceuticals | January 29, 2020

FDA Clears Semaglutide For Cardiac Risk Reduction in Diabetic Patients

Indications expanded for Ozempic and Rybelsus to reduce cardiovascular risk in adults with type 2 diabetes and known heart disease

Indications expanded for Ozempic and Rybelsus to reduce cardiovascular risk in adults with type 2 diabetes and known heart disease

January 29, 2020 - The U.S. Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk's Ozempic (semaglutide) injection 0.5 mg or 1 mg. The new indication is to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.[1] Additional details were added to the Rybelsus (semaglutide) tablets 7 mg or 14 mg prescribing information about the primary analysis for PIONEER 6 trial.

Cardiovascular disease (CVD) is the main cause of death and disability among people with type 2 diabetes.[2] Adults with type 2 diabetes are two to four times more likely to develop CVD than adults without diabetes.[3]

The FDA's decision on semaglutide is based on results from the SUSTAIN 6 cardiovascular outcomes trial (CVOT), which examined the cardiovascular safety of adding Ozempic or placebo to standard-of-care in adults with type 2 diabetes and established cardiovascular disease. In the two-year SUSTAIN 6 trial, semaglutide significantly reduced the risk of the occurrence of a three-component MACE endpoint consisting of cardiovascular death, non-fatal heart attack or non-fatal stroke. 

The estimated relative risk reduction of MACE was 26% vs. placebo (HR 0.74 [95% CI: 0.58, 0.95], p<0.001 for noninferiority, median observation time 2.1 years) with the primary composite outcome occurring in 6.6% of patients treated with semaglutide vs. 8.9% with placebo.[1,4] During the trial, gastrointestinal adverse events were more frequent in the semaglutide group than in the placebo group. The majority of gastrointestinal adverse events occurred during the first 30 weeks.[4]

“There is a well-established link between cardiovascular disease and type 2 diabetes. It’s one of our biggest concerns with type 2 diabetes because even when patients reach their blood sugar targets, the risk of a major adverse CV event remains,” said Todd Hobbs, vice president and U.S. chief medical officer of Novo Nordisk. “Today’s milestone establishes Ozempic as an option for patients to help address two critical aspects of managing type 2 diabetes, blood sugar control and cardiovascular risk reduction, in those with known heart disease.”

Changes to Rybelsus Prescribing Information

The Rybelsus (semaglutide) prescribing information has been updated in section 14 (clinical studies) to include an analysis from the primary endpoint of the PIONEER 6 CVOT showing the hazard ratio for time to first three-component MACE (HR 0.79 [95% CI: 0.57, 1.11]).[5]

In June 2019, Novo Nordisk initiated the SOUL CVOT in 9,642 adults with type 2 diabetes and established cardiovascular disease to further evaluate the cardiovascular effect of Rybelsus. The trial is investigating the effects of Rybelsus on the incidence of MACE vs. placebo in addition to standard-of-care.

About the SUSTAIN 6 Trial

SUSTAIN 6 was an event- and time-driven, pre-approval CVOT for Ozempic. It was a randomized, double-blinded, noninferiority placebo-controlled trial evaluating the cardiovascular safety of Ozempic vs. placebo when added to standard of care in 3,297 adults with type 2 diabetes with established CVD for a minimum observation period of two years.

About Ozempic

Ozempic (semaglutide) injection 0.5 mg or 1 mg is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes mellitus with known heart disease. Semaglutide was cleared by the U.S. Food and Drug Administration (FDA) Dec. 5, 2017, by Health Canada Jan. 4, 2018, by the European Commission Feb. 9, 2018, by the Japanese Ministry of Health, Labour and Welfare March 23, 2018, by Swissmedic July 2, 2018, and by the Brazilian National Health Surveillance Agency Aug. 6, 2018.

  

Medication guide and prescribing information: www.novo-pi.com/ozempic.pdf

 

References:

1. Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk Inc; January 2020.

2. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular disease in diabetes mellitus: Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, Management, and Clinical Considerations. Circulation. 2016;133(24):2459-2502.

3. World Heart Federation. Cardiovascular disease risk factors. Available at: www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/diabetes/. Accessed January 9, 2020.

4. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016:375:1834-1844.

5. Rybelsus [package insert]. Plainsboro, NJ: Novo Nordisk Inc; January 2020.

Related Content

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial.

News | Pharmaceuticals | March 28, 2020 | Dave Fornell, Editor
March 28.
The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an oral, once-daily, non-statin low-density lipoprotein cholesterol (LDL-C) lowering medicine. The drug is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. 
Feature | Pharmaceuticals | February 24, 2020
February 24, 2020 — The U.S.
This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

News | Pharmaceuticals | January 09, 2020
January 9, 2020 – Researchers may have discovered a way to turn back the clock on aging heart muscles in fruit flies,
 Christie Ballantyne

Dr. Christie Ballantyne, professor of medicine and chief of the section of cardiology at Baylor College of Medicine

News | Pharmaceuticals | December 30, 2019
December 30, 2019 — A drug therapy targeting the production of a protein produced by the liver has led to sustained a
Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals | December 16, 2019 | Dave Fornell, Editor
The U.S. Food and Drug Administration (FDA) approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive...
Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after biologic therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after psoriasis biologic drug therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

 

Feature | Pharmaceuticals | July 31, 2019
July 31, 2019 — Researchers found anti-inflammatory drug therapies used to treat moderate to severe psoriasis can sig
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Overlay Init